Literature DB >> 16432045

Therapeutic inertia is an impediment to achieving the Healthy People 2010 blood pressure control goals.

Eni C Okonofua1, Kit N Simpson, Ammar Jesri, Shakaib U Rehman, Valerie L Durkalski, Brent M Egan.   

Abstract

Therapeutic inertia (TI), defined as the providers' failure to increase therapy when treatment goals are unmet, contributes to the high prevalence of uncontrolled hypertension (> or =140/90 mm Hg), but the quantitative impact is unknown. To address this gap, a retrospective cohort study was conducted on 7253 hypertensives that had > or =4 visits and > or =1 elevated blood pressure (BP) in 2003. A 1-year TI score was calculated for each patient as the difference between expected and observed medication change rates with higher scores reflecting greater TI. Antihypertensive therapy was increased on 13.1% of visits with uncontrolled BP. Systolic BP decreased in patients in the lowest quintile of the TI score but increased in those in the highest quintile (-6.8+/-0.5 versus +1.8+/-0.6 mm Hg; P<0.001). Individuals in the lowest TI quintile were &amp;33 times more likely to have their BP controlled at the last visit than those in highest quintile (odds ratio, 32.7; 95% CI, 25.1 to 42.6; P<0.0001). By multivariable analysis, TI accounted for &amp;19% of the variance in BP control. If TI scores were decreased &amp;50%, that is, increasing medication dosages on &amp;30% of visits, BP control would increase from the observed 45.1% to a projected 65.9% in 1 year. This study confirms the high rate of TI in uncontrolled hypertensive subjects. TI has a major impact on BP control in hypertensive subjects receiving regular care. Reducing TI is critical in attaining the Healthy People 2010 goal of controlling hypertension in 50% of all patients.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16432045     DOI: 10.1161/01.HYP.0000200702.76436.4b

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  163 in total

Review 1.  Should two-drug initial therapy for hypertension be recommended for all patients?

Authors:  Jennifer B Cowart; Addison A Taylor
Journal:  Curr Hypertens Rep       Date:  2012-08       Impact factor: 5.369

2.  Blood pressure-lowering efficacy of an olmesartan medoxomil/hydrochlorothiazide-based treatment algorithm in elderly patients (age ≥65 years) stratified by age, sex and race: subgroup analysis of a 12-week, open-label, single-arm, dose-titration study.

Authors:  Joel Neutel; Dean J Kereiakes; Kathy A Stoakes; Jen-Fue Maa; Ali Shojaee; William F Waverczak
Journal:  Drugs Aging       Date:  2011-06-01       Impact factor: 3.923

3.  Testing for clinical inertia in medication treatment of bipolar disorder.

Authors:  Dominic Hodgkin; Elizabeth L Merrick; Peggy L O'Brien; Thomas G McGuire; Sue Lee; Thilo Deckersbach; Andrew A Nierenberg
Journal:  J Affect Disord       Date:  2016-06-21       Impact factor: 4.839

4.  Association of Low-Dose Triple Combination Therapy With Therapeutic Inertia and Prescribing Patterns in Patients With Hypertension: A Secondary Analysis of the TRIUMPH Trial.

Authors:  Nelson Wang; Abdul Salam; Ruth Webster; Asita de Silva; Rama Guggilla; Sandrine Stepien; Jayanthi Mysore; Laurent Billot; Stephen Jan; Pallab K Maulik; Nitish Naik; Vanessa Selak; Simon Thom; Dorairaj Prabhakaran; Anushka Patel; Anthony Rodgers
Journal:  JAMA Cardiol       Date:  2020-11-01       Impact factor: 14.676

5.  Effect of pay-for-performance incentives on quality of care in small practices with electronic health records: a randomized trial.

Authors:  Naomi S Bardach; Jason J Wang; Samantha F De Leon; Sarah C Shih; W John Boscardin; L Elizabeth Goldman; R Adams Dudley
Journal:  JAMA       Date:  2013-09-11       Impact factor: 56.272

6.  Reducing clinical inertia in hypertension treatment: a pragmatic randomized controlled trial.

Authors:  Amy G Huebschmann; Trina Mizrahi; Alyssa Soenksen; Brenda L Beaty; Thomas D Denberg
Journal:  J Clin Hypertens (Greenwich)       Date:  2012-03-16       Impact factor: 3.738

7.  Health coaching to improve hypertension treatment in a low-income, minority population.

Authors:  David Margolius; Thomas Bodenheimer; Heather Bennett; Jennifer Wong; Victoria Ngo; Guillermo Padilla; David H Thom
Journal:  Ann Fam Med       Date:  2012 May-Jun       Impact factor: 5.166

8.  Predicting changes in hypertension control using electronic health records from a chronic disease management program.

Authors:  Jimeng Sun; Candace D McNaughton; Ping Zhang; Adam Perer; Aris Gkoulalas-Divanis; Joshua C Denny; Jacqueline Kirby; Thomas Lasko; Alexander Saip; Bradley A Malin
Journal:  J Am Med Inform Assoc       Date:  2013-09-17       Impact factor: 4.497

9.  Prevalence and Comorbidities of Resistant Hypertension: A Collaborative Population-Based Observational Study.

Authors:  Simone Romano; Chiara Idolazzi; Cristiano Fava; Luigi Fondrieschi; Mario Celebrano; Pietro Delva; Lorella Branz; Angela Donato; Andrea Dalbeni; Pietro Minuz
Journal:  High Blood Press Cardiovasc Prev       Date:  2018-06-29

10.  Successful treatment of hypertension accounts for improvements in markers of diastolic function - a pilot study comparing hydrochlorothiazide-based and amlodipine-based treatment strategies.

Authors:  Kofo O Ogunyankin; Andrew G Day
Journal:  Can J Cardiol       Date:  2009-12       Impact factor: 5.223

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.